NCT04848454 2022-10-18
Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy
Peking University First Hospital
Phase 2 Unknown
Clinical Trials
4 trialsNCT05263882 2022-03-03
Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 2 Unknown
NCT04624711 2021-05-21
Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT04498793 2020-09-03
Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown